Spero Therapeutics (NASDAQ:SPRO) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

13 May 2026, 20:38 by Jessica Moore · The Cerbat Gem

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05, FiscalAI reports. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $43.34 million. Spero Therapeutics had a net margin of 12.83% and a return on equity of 22.53%.

Spero Therapeutics Stock Performance

Shares of SPRO stock traded down $0.10 on Wednesday, reaching $2.44. 673,527 shares of the company were exchanged, compared to its average volume of 438,896. The company has a market cap of $141.28 million, a price-to-earnings ratio of 20.34 and a beta of 1.43. The business has a 50-day moving average price of $2.54 and a 200 day moving average price of $2.42. Spero Therapeutics has a 1 year low of $0.63 and a 1 year high of $3.22.

Analysts Set New Price Targets

Several analysts recently commented on SPRO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Sunday, March 29th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Spero Therapeutics presently has a consensus rating of “Reduce”.

Read Our Latest Research Report on Spero Therapeutics

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 25,240 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $2.51, for a total transaction of $63,352.40. Following the completion of the sale, the insider owned 986,851 shares of the company’s stock, valued at $2,476,996.01. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Spero Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in shares of Spero Therapeutics during the second quarter worth about $43,000. Millennium Management LLC purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $56,000. Dimensional Fund Advisors LP purchased a new stake in shares of Spero Therapeutics during the third quarter worth about $55,000. XTX Topco Ltd purchased a new stake in shares of Spero Therapeutics during the second quarter worth about $100,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $88,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

(Get Free Report)

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.